Jacobson Pharma Corporation Ltd. has released its 2024/2025 Annual Report, highlighting the company's sustained growth and resilience despite challenging economic conditions. The report indicates that the Group continued its growth trajectory with consistent operational performance and solid business results. Key contributors to this performance include an aging population, higher prevalence of chronic diseases, and growing public health awareness, which have bolstered demand for healthcare services and medications. The Group's expansion in specialty medicines and the broader generic drug market played a significant role in maintaining revenue growth. The full report can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobson Pharma Corporation Ltd. published the original content used to generate this news brief on July 03, 2025, and is solely responsible for the information contained therein.